Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.
Eom KS, Kim SJ, Lee JJ, Suh C, Kim JS, Yoon SS, Kim BS, Kang HJ, Choi YJ, Kim CS, Kim YS, Kwak JY, Kim YJ, Joo YD, Mun YC, Jo DY, Park JS, Park CY, Kim SH, Min CK.
Eom KS, et al. Among authors: park js, park cy.
Biomed Res Int. 2014;2014:245247. doi: 10.1155/2014/245247. Epub 2014 Jun 23.
Biomed Res Int. 2014.
PMID: 25050331
Free PMC article.
Clinical Trial.